Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
NEW YORK, April 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
What is the procedure, for establishing reimbursement for an IVD test product? What companies have been successful and how? What changes will IVD makers face in the near-term. This Kalorama Information report, Reimbursement for In Vitro Diagnostic Tests, answers these questions and provides authoritative data for IVD business planners.
One of the critical factors for the success of an IVD product is reimbursement. Reimbursement is a critical component of the health care landscape and will continue to have a major impact on the continued usage of established products as well as product innovation and the market success of new technologies since products without solid reimbursement will not achieve widespread utilization and/or will not provide the revenues for their developers to continue to introduce new products.
This report, Reimbursement for In Vitro Diagnostic (IVD) Tests examines the U.S. reimbursement system for IVD tests, focusing on key issues of current concern to industry. It covers only commercialized tests, specifically excluding those that are developmental or used primarily for research purposes.
As part of its analysis, the report has the following:
Explanation of the Process for Reimbursement of IVD Products Under Medicare
Upcoming Medicare Reimbursement Cuts
Recent FDA Approvals of IVD Devices
Oversight of LDTs, Pilot IVD Triage Program, UDI Rule and Other Regulatory Initiatives
Office of the General Inspector Recommendations
ICD Codes, Laboratory NCD Codes and CLFS Test Codes
Gap-Fill Rates for Molecular Diagnostics
The Assessment of Novel Tests
Case Studies of Successful IVD Products and Lessons for New Entrants
The key open issues facing IVD reimbursement may be broadly grouped into four categories that comprise budget tightening, including Medicare cost cutting; outdated CLFS; FDA initiatives encompassing both rulemaking and new regulatory pathways; and challenges assessing new tests.
Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends. Case studies of successful reimbursement strategies are included to illustrate how product developers obtain reimbursement for new IVD tests.
CHAPTER ONE: EXECUTIVE SUMMARY
Medical Device and In Vitro Diagnostics (IVD) Testing Reimbursement
Scope and Methodology
Important Issues in IVD Reimbursement
Case Studies in Obtaining IVD Reimbursement
CHAPTER TWO: CMS AND PRIVATE INSURANCE REIMBURSEMENT FOR
The U.S. Health Care Reimbursement System
History of IVD Reimbursement Under Medicare
Billing for Stored Specimens
The Patient Protection and Affordable Care Act (PPACA)
FDA Oversight of IVDMIAs
Laboratory National Coverage Determinations
Multi-Analyte Assays with Algorithmic Analyses
Recent IVD Device Approvals
CHAPTER THREE: IMPORTANT ISSUES IN IVD REIMBURSEMENT
Medicare Reimbursement Cuts
Oversight of LDTs
Pilot IVD Triage Program
Challenges Assessing New Tests
CHAPTER FOUR: CASE STUDIES IN OBTAINING
List of Exhibits
LIST OF EXHIBIT S
CHAPTER ONE: EXECUTIVE SUMMARY
Figure 1-1 FDA Approvals of IVD Devices
CHAPTER TWO: CMS AND PRIVATE INSURANCE REIMBURSEMENT FOR IVDS
Table 2-1 2013 CLFS Selected Test Codes
Table 2-2 List of ICD Codes, 2013
Table 2-3 Laboratory NCDs, 2013
Table 2-4 New and Reconsidered CLFS Test Codes, 2013 (Excludes Molecular Pathology & Multi-Analyte Assays with Algorithmic Analyses)
Table 2-5 2013 CLFS Gap-Fill Rates for Molecular Diagnostics
Table 2-6 Recent IVD Device Approvals
Contact Clare: email@example.com
Intl: +1 339-368-6001
©2012 PR Newswire. All Rights Reserved.
7831 N. Business Park Drive